UpcomingPDUFA target action date

Lorundrostat

Mineralys Therapeutics (MLYS)

Marketer take

Would compete directly with the recently approved Baxfendy in add-on hypertension, so expect head-to-head positioning in primary care.

Sponsor company
Mineralys Therapeutics (MLYS)
Indication
Hypertension, in combination with other antihypertensives
Therapeutic area
Cardiovascular
Event
PDUFA target action date
Date
Dec 22, 2026
Status
Upcoming
Source
SEC filing
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move